BNET Industries
Sepracor Inc. (SEPR) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $1.2B
- Profit
- Dec 31 2007
- $58.3M
- Market Cap
- Sep 04 2008
- $2.0B
Latest News and Analysis
At Sepracor, a Cost-Cutting Exercise Proves Expensive
Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 sales force positions." The company said it needed to make the layoffs because, by last October, its revenues were falling....
Sepracor, Inc. Q2 2008 Earnings Call
Sepracor Inc. SEPR Q2 FY08 Earnings Call
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) announced today that it has completed the acquisition of Oryx Pharmaceuticals Inc., an affiliate of the Arrow Group. Oryx is a specialty pharmaceutical company that markets branded prescription pharmaceutical products to physician specialists and hospitals within Canada and is focused in the cardiovascular,...
Sepracor Inc. Q1 2008 Earnings Call Transcript
Sepracor Inc. Q1 2008 Earnings Call Transcript
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
* Acquisition creates a commercial platform for Sepracor in the Canadian specialty pharmaceutical market
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX®/Ipratropium Inhalation Solution Combination
* XOPENEX([R])/ipratropium inhalation solution product is Phase III-ready with potential launch in 2011 for the treatment of chronic obstructive pulmonary disease COPD
Sepracor Inc. Reports First Quarter 2008 Results, Certain Strategic Initiatives and Settlement of XOPENEX® Patent Litigation with Breath Limited
Financial Highlights*
Sepracor Launches "My Allergies in America" Web Site, a New Online Resource for Physicians and Nasal Allergy Sufferers
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) announced today the launch of "My Allergies in America" (www.myallergiesinamerica.com), a comprehensive resource for physicians and consumers based on the two-part, landmark "Allergies in America" survey of adults, adolescents and children with allergic rhinitis. The survey, endorsed by the American College of Allergy,...
Sepracor Presents Safety Data on OMNARIS™AQ and OMNARIS™ HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology
* Ciclesonide is a corticosteroid with a unique activation mechanism and is a prodrug activated by intracellular esterases following oral or nasal inhalation
Sepracor Presents OMNARIS™ HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology
* Ciclesonide is a corticosteroid with a unique activation mechanism and is a prodrug activated by intracellular esterases following oral or nasal inhalation
Sepracor, Inc. Q4 2007 Earnings Call Transcript
Sepracor, Inc. Q4 2007 Earnings Call Transcript
Sepracor shifts Lunesta DTC biz
SEPRACOR HAS shifted its Lunesta DTC advertising business from McCann Erickson to Kaplan Thaler Group.
Sepracor Inc. Reports 2007 Fourth Quarter and Full-Year Results, Forecasts Stronger Revenue Growth for 2008
Financial Highlights
KAPLAN THALER NABS $300M LUNESTA BIZ.(News)(Kaplan Thaler Group tapped by Sepracor Inc. for the marketing of its sleep-aid brand Lunesta)(Brief article)
Byline: rupal parekh Byline: rupal parekh
Sepracor Acquires Exclusive U.S. Rights to Nycomed's ALVESCO® HFA and OMNARIS™ AQ Products as Well as Ciclesonide Pipeline
* Ciclesonide is the active ingredient in ALVESCO HFA Inhalation Aerosol for asthma and OMNARIS AQ Nasal Spray for allergic rhinitis
Sepracor Announces Internal Review of Government Price Reporting Matters
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) announced today that it is conducting a review of its government price reporting. On January 17, 2008, Sepracor notified the Centers for Medicare and Medicaid Services ("CMS") that the Company has identified potential errors in its Medicaid Best Price ("Best Price"), including the...
Timothy J. Barberich to Resign as Executive Chairman of Sepracor and Will Continue to Serve as Chairman of the Board
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that Timothy J. Barberich will retire as an executive of the company on or prior to May 13, 2008 and is expected to continue to serve as Chairman of Sepracor's Board of Directors. Mr. Barberich also plans to serve as an...
Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada
BIA 2-093, Eslicarbazepine Acetate, has Completed Large-Scale Phase III Clinical Studies
Sepracor, King to slash sales forces
SMALL PHARMA is taking a cue from its big pharma brethren as it trims its sales force size to improve market position.
Sepracor Inc. Announces Completion of SEC Investigation
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that it received notice from the Securities and Exchange Commission SEC that the investigation concerning the company's historical stock option granting practices has been completed and that no enforcement action was recommended.
- Next »
- page 1 of 9
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- FDA (12 results)
- Earnings (10 results)
- Seeking Alpha (10 results)
- Financial Accounting (10 results)
- Finance (10 results)
- Call Transcript (9 results)
- Webcast (9 results)
- stock (9 results)
- blog (4 results)
- revenue (4 results)
- stock market (4 results)
- Nasdaq Stock Market Inc. (3 results)
- Sales (3 results)
- Apple Inc. (3 results)
- patent (3 results)
- brand (3 results)
- Incorporated: 1984
- CEO: Mr. Adrian Adams
Sepracor is pharmaceutical company that develops and commercializes products prescribed by physicians and specialists. At Dec 31 2007, Co.'s marketed products included: XOPENEX® Inhalation Solution for the treatment or prevention of bronchospasm in patients six years of age and older with reversible obstructive airway disease; XOPENEX HFA® Inhalation Aerosol for the treatment or prevention of bronchospasm in adults, adolescents and children of four years of age and older with reversible obstructive airway disease; BROVANA® Inhalation Solution for the treatment of bronchoconstriction patients with chronic obstructive pulmonary disease; and LUNESTA® for the treatment of insomnia in adults.
Key Competitors
Sepracor Inc. Company Info
Board of Directors
Mr. Timothy J. Barberich
Chairman
Mr. William J. O'Shea
Vice-Chairman
Mr. Robert J. Cresci
Lead Director
Mr. Digby W. Barrios
Mr. Alan A. Steigrod
Mr. Timothy J. Rink
Mr. James F. Mrazek
Ms. Lisa Ricciardi
Contact Information
84 Waterford Drive
Marlborough, MA
508 481-6700
NAICS Code
Pharmaceutical and Medicine Manufacturing: 3254
